 ROCKVILLE, Md., Nov. 02, 2020 GLOBE NEWSWIRE -- Rexahn Pharmaceuticals, Inc. NASDAQ:REXN Rexahn announced today that at its special meeting of stockholders held on November 2, 2020, Rexahns stockholders approved all of the proposals presented, including: i the issuance of shares of Rexahn common stock pursuant to the Agreement and Plan of Merger and Reorganization, dated June 17, 2020, as amended, by and among Rexahn, Razor Merger Sub, Inc. and Ocuphire Pharma, Inc. Ocuphire and the change of control of Rexahn resulting from the merger; ii a reverse stock split of Rexahn common stock, at a ratio of one new share for every 3 to 5 shares outstanding, with such final ratio to be approved by Rexahns board of directors; iii changing the name of Rexahn from Rexahn Pharmaceuticals, Inc. to Ocuphire Pharma, Inc.; iv the adoption of the Ocuphire Pharma, Inc. 2020 Equity Incentive Plan; and v the issuance of shares of Rexahn common stock upon the exercise of warrants to be issued in the pre-merger financing and the issuance of additional shares of Rexahn common stock that may be issued following the closing of the pre-merger financing. 